GH - Guardant Health Inc logo

GH

Guardant Health Inc

Revenue grew 100% of years5Y
Hold

Guardant Health provides blood and tissue tests for cancer detection and monitoring, including liquid biopsies like Guardant360 and colorectal screening tests. Their services offer genomic insights to improve cancer treatment and research outcomes.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$1,575today

Score Overview

1 Year
Score
Net Growth-8.93%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth20.48%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.0
Net Growth-11.77%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth216.63%
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Score
Net Growth-433.06%
Net Trend50%
Net Income Consistency
Rev Growth13x
Rev TrendEvery year
Revenue Consistency

See the full market ranking โ†’

Guardant Health Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 286M to $ 982M and net income went from -$ 253M to -$ 416M. Revenue increased in every one of those 5 years; net income in 3.

Guardant Health Inc currently holds a 5-year HDB Score of 6.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-13
$ 159.54โ€”
1 Year2025-08-13
$ 58.57172.39%
5 Years2021-08-13
$ 101.2857.52%
All Time2018-10-04
$ 32.20395.47%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 1.18B-$ 453M$ 1.05B
2025$ 982M-$ 416M$ 1.20B
2024$ 739M-$ 436M$ 839M
2023$ 563M-$ 479M$ 1.16B
2022$ 449M-$ 654M$ 1.01B
2021$ 373M-$ 405M$ 932M
2020$ 286M-$ 253M$ 1.79B
2019$ 214M-$ 75M$ 522M
IPO2018$ 90M-$ 85M$ 418M

Explore beyond GH

You're looking at Guardant Health Inc. Members apply the same fundamental framework across all 3,859 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies